局部晚期非小细胞肺癌的心脏保护放疗
本研究对20例局部晚期非小细胞肺癌患者按IDEAL-CRT等毒性方案生成基线VMAT计划,并添加心脏平均剂量等限制目标重新优化。结果显示心脏平均剂量、VHeart-50-Gy和VLAwall-63-Gy分别绝对下降4.8 Gy、2.2%和2.4%,心脏平均剂量降低预计带来最大总生存改善,预测死亡HR为0.806。
要点
- 重新优化后心脏平均剂量绝对降低4.8 Gy,VHeart-50-Gy和VLAwall-63-Gy分别绝对降低2.2%和2.4%。
- 心脏平均剂量降低对应的预测死亡HR为0.806,预计带来最大总生存改善。
- 基线心脏平均剂量高于已发表队列中位值的患者,平均降低达8.8 Gy。
核心结论
- 局部晚期非小细胞肺癌放疗中的心脏照射可大幅降低,其中心脏平均剂量降低带来的预测生存改善最大。
研究设计与样本
- 对20例局部晚期非小细胞肺癌患者按IDEAL-CRT等毒性协议创建基线VMAT计划,并添加心脏平均剂量等限制目标后重新优化。
主要发现
- 重新优化后心脏平均剂量、VHeart-50-Gy和VLAwall-63-Gy分别绝对下降4.8 Gy、2.2%和2.4%。
- 心脏平均剂量降低同时带来VHeart-50-Gy和VLAwall-63-Gy等其他心脏照射指标的连带下降。
- 基线心脏平均剂量超过已发表系列中位值的患者,平均降低达8.8 Gy。
关键数值与推荐
- 心脏平均剂量降低对应的预测死亡HR为0.806。
- 以0.05显著性和80%把握度检验生存改善的随机试验需1140例患者。
- 在富集基线心脏平均剂量较高的人群中,对应预测HR可在招募359例患者的试验中检验。
临床怎么用
- 在局部晚期非小细胞肺癌光子放疗计划优化中可添加心脏平均剂量限制目标以降低心脏照射。
- 对基线心脏平均剂量较高的患者,心脏剂量降低幅度更大,可优先考虑心脏保护优化。
局限性
- 研究基于20例患者的计划剂量学分析,生存改善为基于独立数据关联的预测而非临床结局验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have carried out a study to determine the scope for reducing heart doses in photon beam radiotherapy of locally advanced non-small cell lung cancer (LA-NSCLC). MATERIALS AND METHODS: Baseline VMAT plans were created for 20 LA-NSCLC patients following the IDEAL-CRT isotoxic protocol, and were re-optimized after adding an objective limiting heart mean dose (MDHeart). Reductions in MDHeart achievable without breaching limits on target coverage or normal tissue irradiation were determined. The process was repeated for objectives limiting the heart volume receiving ≥ 50 Gy (VHeart-50-Gy) and left atrial wall volume receiving ≥ 63 Gy (VLAwall-63-Gy). RESULTS: Following re-optimization, mean MDHeart, VHeart-50-Gy and VLAwall-63-Gy values fell by 4.8 Gy and 2.2% and 2.4% absolute respectively. On the basis of associations observed between survival and cardiac irradiation in an independent dataset, the purposefully-achieved reduction in MDHeart is expected to lead to the largest improvement in overall survival. It also led to useful knock-on reductions in many measures of cardiac irradiation including VHeart-50-Gy and VLAwall-63-Gy, providing some insurance against survival being more strongly related to these measures than to MDHeart. The predicted hazard ratio (HR) for death corresponding to the purposefully-achieved mean reduction in MDHeart was 0.806, according to which a randomized trial would require 1140 patients to test improved survival with 0.05 significance and 80% power. In patients whose baseline MDHeart values exceeded the median value in a published series, the average MDHeart reduction was particularly large, 8.8 Gy. The corresponding predicted HR is potentially testable in trials recruiting 359 patients enriched for greater MDHeart values. CONCLUSIONS: Cardiac irradiation in RT of LA-NSCLC can be reduced substantially. Of the measures studied, reduction of MDHeart led to the greatest predicted increase in survival, and to useful knock-on reductions in other cardiac irradiation measures reported to be associated with survival. Potential improvements in survival can be trialled more efficiently in a population enriched for patients with greater baseline MDHeart levels, for whom larger reductions in heart doses can be achieved.
引用
- Turtle L, Bhalla N, Willett A, et al. Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer. Radiat Oncol. 2021. PMID: 34082782. doi:10.1186/s13014-021-01824-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。